Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report published on Friday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright dropped their price objective on shares of Minerva Neurosciences from $7.00 to $5.00 and set a neutral rating on the stock in a report on Wednesday, August 7th.

Minerva Neurosciences Stock Down 2.1 %

NASDAQ NERV opened at $2.74 on Friday. Minerva Neurosciences has a 52 week low of $2.26 and a 52 week high of $13.49. The company has a 50 day moving average price of $3.00 and a 200 day moving average price of $3.19. The firm has a market cap of $19.16 million, a PE ratio of -0.61 and a beta of 0.15.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). On average, equities research analysts anticipate that Minerva Neurosciences will post -1.89 earnings per share for the current fiscal year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.